Earnings call transcript: DexCom beats Q1 2026 forecasts, stock rises

DexCom beat Q1 2026 expectations with EPS of $0.56 versus $0.47 consensus and revenue of $1.19 billion versus $1.17 billion, while aftermarket shares rose 3.41% to $57.99. Gross margin expanded to 63.5% from 57.5% a year ago, operating margin rose to 22.2%, and management lifted full-year operating profit margin guidance to 23%-23.5% and adjusted EBITDA margin guidance to 31%-31.5%. The quarter was supported by strong 15% revenue growth, including 26% international growth, and continued momentum from the G7 15-Day launch.

Analysis

DXCM’s quarter is less about a one-time earnings beat and more about evidence that the business has crossed from demand recovery into operating leverage. The key second-order signal is that margin expansion is now being driven by product mix and execution, not just price, which means upside can persist even if top-line growth moderates. That matters because the stock is still trading near levels where the market seems to be discounting a low-growth medtech, while management is implicitly arguing for a durable re-rating as access broadens.

The bigger catalyst is not the current quarter; it is the coverage funnel. Every incremental payer win increases physician willingness to write broadly, which should raise both new starts and retention through higher perceived “standard of care” status. That creates a flywheel: more access drives more utilization data, which strengthens reimbursement negotiations, which then lowers CAC per patient over time. Internationally, the asymmetry is even better because reimbursement wins can unlock faster share gains without needing a fully saturated U.S.-style sales model.

The main risk is that the market may be overestimating how quickly the non-insulin opportunity monetizes. CMS timing can slip, and even if coverage expands, adoption may lag if primary care workflows remain frictional; that makes the near-term upside more dependent on 15-day conversion and international execution than on the headline TAM narrative. A second-order negative is cost sensitivity: the company is effectively telling you gross margin can be protected, but only if transport/resin inflation doesn’t bite harder in 2H. If energy stays elevated, the market could punish multiple expansion despite strong fundamentals.

Contrarian take: the consensus is likely still underappreciating how much of the value creation comes from improved retention and higher lifetime value, not just new patient adds. In other words, this is increasingly a compounding story, not a pure coverage-event story. That favors owning the stock through catalysts rather than waiting for perfect visibility, because the operating model is quietly de-risking itself quarter by quarter.

Key Decisions for Investors

• Go long DXCM into the May Investor Day / ADA window with a 4-8 week horizon; use the stock’s proximity to recent lows as a favorable entry, with upside driven by multiple expansion if management confirms CMS timing and 15-day conversion >50% by year-end.
• Buy DXCM Jan-2027 calls or call spreads instead of common to express the CMS/non-insulin optionality; the risk/reward is favorable because the market is underpricing a delayed but material access unlock while downside is capped to premium.
• Pair trade: long DXCM / short a slower-growing large-cap medtech peer with weaker reimbursement momentum over the next 1-3 months; the relative trade should benefit if investors reward operating leverage and access wins over static product portfolios.
• Trim or hedge DXCM if oil/fuel/resin headlines re-accelerate over the next 1-2 quarters; the company has flagged a 50-100 bps gross margin risk band, so a sustained energy spike is the cleanest fundamental bear case.
• Use any post-earnings strength to add on pullbacks rather than chase; the better setup is to accumulate on consolidation ahead of the RCT readout, since that event can re-anchor the non-insulin debate and support a second leg higher.